|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCP110 |
Gene summary for CCP110 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCP110 | Gene ID | 9738 |
| Gene name | centriolar coiled-coil protein 110 | |
| Gene Alias | CP110 | |
| Cytomap | 16p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | O43303 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9738 | CCP110 | LZE4T | Human | Esophagus | ESCC | 2.28e-07 | 1.75e-01 | 0.0811 |
| 9738 | CCP110 | LZE7T | Human | Esophagus | ESCC | 5.15e-03 | 2.81e-01 | 0.0667 |
| 9738 | CCP110 | LZE24T | Human | Esophagus | ESCC | 5.19e-04 | 1.48e-01 | 0.0596 |
| 9738 | CCP110 | P1T-E | Human | Esophagus | ESCC | 2.49e-03 | 1.85e-01 | 0.0875 |
| 9738 | CCP110 | P2T-E | Human | Esophagus | ESCC | 2.04e-33 | 6.74e-01 | 0.1177 |
| 9738 | CCP110 | P4T-E | Human | Esophagus | ESCC | 9.89e-08 | 1.46e-01 | 0.1323 |
| 9738 | CCP110 | P5T-E | Human | Esophagus | ESCC | 4.10e-07 | 6.31e-02 | 0.1327 |
| 9738 | CCP110 | P8T-E | Human | Esophagus | ESCC | 5.78e-14 | 2.14e-01 | 0.0889 |
| 9738 | CCP110 | P10T-E | Human | Esophagus | ESCC | 1.70e-13 | 1.33e-01 | 0.116 |
| 9738 | CCP110 | P11T-E | Human | Esophagus | ESCC | 3.75e-05 | 1.55e-01 | 0.1426 |
| 9738 | CCP110 | P12T-E | Human | Esophagus | ESCC | 2.26e-13 | 2.20e-01 | 0.1122 |
| 9738 | CCP110 | P15T-E | Human | Esophagus | ESCC | 4.31e-11 | 2.37e-01 | 0.1149 |
| 9738 | CCP110 | P16T-E | Human | Esophagus | ESCC | 1.59e-21 | 4.05e-01 | 0.1153 |
| 9738 | CCP110 | P20T-E | Human | Esophagus | ESCC | 6.03e-06 | 1.34e-01 | 0.1124 |
| 9738 | CCP110 | P21T-E | Human | Esophagus | ESCC | 1.42e-12 | 1.39e-01 | 0.1617 |
| 9738 | CCP110 | P22T-E | Human | Esophagus | ESCC | 1.83e-03 | 9.49e-02 | 0.1236 |
| 9738 | CCP110 | P23T-E | Human | Esophagus | ESCC | 1.05e-06 | 1.84e-01 | 0.108 |
| 9738 | CCP110 | P24T-E | Human | Esophagus | ESCC | 1.97e-06 | 7.55e-02 | 0.1287 |
| 9738 | CCP110 | P26T-E | Human | Esophagus | ESCC | 6.50e-12 | 2.19e-01 | 0.1276 |
| 9738 | CCP110 | P27T-E | Human | Esophagus | ESCC | 1.65e-08 | 1.47e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
| GO:000091016 | Esophagus | ESCC | cytokinesis | 115/8552 | 173/18723 | 2.48e-08 | 4.68e-07 | 115 |
| GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
| GO:190211514 | Esophagus | ESCC | regulation of organelle assembly | 116/8552 | 186/18723 | 3.15e-06 | 3.53e-05 | 116 |
| GO:00070982 | Esophagus | ESCC | centrosome cycle | 85/8552 | 130/18723 | 4.41e-06 | 4.69e-05 | 85 |
| GO:00310233 | Esophagus | ESCC | microtubule organizing center organization | 92/8552 | 143/18723 | 5.04e-06 | 5.31e-05 | 92 |
| GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
| GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
| GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
| GO:01200347 | Esophagus | ESCC | positive regulation of plasma membrane bounded cell projection assembly | 64/8552 | 105/18723 | 1.15e-03 | 5.70e-03 | 64 |
| GO:00324653 | Esophagus | ESCC | regulation of cytokinesis | 57/8552 | 92/18723 | 1.20e-03 | 5.88e-03 | 57 |
| GO:190211611 | Esophagus | ESCC | negative regulation of organelle assembly | 28/8552 | 41/18723 | 2.88e-03 | 1.21e-02 | 28 |
| GO:19021174 | Esophagus | ESCC | positive regulation of organelle assembly | 42/8552 | 67/18723 | 3.72e-03 | 1.52e-02 | 42 |
| GO:00513025 | Esophagus | ESCC | regulation of cell division | 97/8552 | 177/18723 | 8.93e-03 | 3.12e-02 | 97 |
| GO:001063912 | Liver | HCC | negative regulation of organelle organization | 204/7958 | 348/18723 | 7.67e-10 | 2.37e-08 | 204 |
| GO:003134611 | Liver | HCC | positive regulation of cell projection organization | 193/7958 | 353/18723 | 2.28e-06 | 3.08e-05 | 193 |
| GO:19021151 | Liver | HCC | regulation of organelle assembly | 110/7958 | 186/18723 | 3.30e-06 | 4.34e-05 | 110 |
| GO:0045786 | Liver | HCC | negative regulation of cell cycle | 204/7958 | 385/18723 | 1.84e-05 | 1.99e-04 | 204 |
| GO:000091011 | Liver | HCC | cytokinesis | 100/7958 | 173/18723 | 3.38e-05 | 3.39e-04 | 100 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCP110 | SNV | Missense_Mutation | c.2575N>C | p.Val859Leu | p.V859L | O43303 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | PD | ||
| CCP110 | SNV | Missense_Mutation | c.2434N>A | p.Arg812Ser | p.R812S | O43303 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCP110 | SNV | Missense_Mutation | c.2108N>T | p.Ser703Phe | p.S703F | O43303 | protein_coding | tolerated(0.07) | possibly_damaging(0.847) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| CCP110 | SNV | Missense_Mutation | c.772G>A | p.Glu258Lys | p.E258K | O43303 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCP110 | deletion | In_Frame_Del | c.522_542delNNNNNNNNNNNNNNNNNNNNN | p.Asp175_His181del | p.D175_H181del | O43303 | protein_coding | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR | |||
| CCP110 | SNV | Missense_Mutation | c.2162N>G | p.Ser721Cys | p.S721C | O43303 | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| CCP110 | SNV | Missense_Mutation | rs781615627 | c.1471N>A | p.Ala491Thr | p.A491T | O43303 | protein_coding | tolerated(0.52) | benign(0.001) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CCP110 | SNV | Missense_Mutation | c.1717N>T | p.Asn573Tyr | p.N573Y | O43303 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
| CCP110 | SNV | Missense_Mutation | novel | c.625N>A | p.Glu209Lys | p.E209K | O43303 | protein_coding | tolerated(0.09) | benign(0.23) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CCP110 | SNV | Missense_Mutation | c.2257N>G | p.Phe753Val | p.F753V | O43303 | protein_coding | tolerated(0.19) | benign(0.23) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |